Man Group
BOLT icon

Man Group’s Bolt Biotherapeutics BOLT Stock Holding History

Man Group’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,224
Closed -$35.8K – 2022
2022
Q4 		$31.8K Buy
1,224
+329
+37% +$9.02K ﹤0.01% 1970
2022
Q3 		$26K Buy
+895
New +$37K ﹤0.01% 1924
2022
Q2 		– Hold
0
– – – 1966

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group's BOLT Position: Q1 2023 in Review

Man Group sold out of Bolt Biotherapeutics (BOLT) in Q1 2023, closing a stake of 1,224 shares — an estimated $35.8K sold.

Man Group first reported a position in BOLT in Q3 2022 and held it in 2 quarters. The position peaked at $31.8K in Q4 2022. 40 funds tracked by Wall St. Rank hold BOLT as of Q1 2023.

  • Man Group reported no remaining Bolt Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 1,224 Bolt Biotherapeutics shares in Q1 2023, an estimated $35.8K.
  • Man Group first reported a position in Bolt Biotherapeutics in Q3 2022 and held it in 2 quarters.
  • Man Group's Bolt Biotherapeutics position peaked at $31.8K in Q4 2022.
  • 40 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.